

## Screening and early detection of prostate cancer: PSA and beyond

Poster Session 18

Saturday, 25 March  
14:15 - 15:45

**Location:** Room Stockholm, North Hall (Level 1)

**Chairs:** F. Abdollah, Detroit (US)  
F.C. Hamdy, Oxford (GB)  
M.J. Roobol, Rotterdam (NL)

### Aims and objectives of this session

The session is aimed at addressing the multi-variable risk assessment to optimize the use of screening and early detection strategies in prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

- 234 **An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial**  
By: Johnston T.<sup>1</sup>, Lamb A.<sup>1</sup>, Vowler S.<sup>2</sup>, Xiong T.<sup>1</sup>, Moore A.<sup>1</sup>, Holding P.<sup>3</sup>, Herbert P.<sup>1</sup>, Davis M.<sup>4</sup>, Lane A.<sup>4</sup>, Donovan J.<sup>4</sup>, Hamdy F.<sup>5</sup>, Neal D.<sup>1</sup>  
**Institutes:**<sup>1</sup>University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, <sup>2</sup>Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom, <sup>3</sup>University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, <sup>4</sup>University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom, <sup>5</sup>University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom
- 235 **At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study**  
By: Carlsson S.<sup>1</sup>, Arnsrud Godtman R.<sup>2</sup>, Holmberg E.<sup>3</sup>, Lilja H.<sup>4</sup>, Månsson M.<sup>2</sup>, Stranne J.<sup>2</sup>, Hugosson J.<sup>2</sup>  
**Institutes:**<sup>1</sup>Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, <sup>2</sup>Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden, <sup>3</sup>Sahlgrenska Academy, Dept. of Oncology, Gothenburg, Sweden, <sup>4</sup>Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Malmö, Sweden
- 236 **Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic**  
By: Margel D.<sup>1</sup>, Mano R.<sup>1</sup>, Benjaminov O.<sup>2</sup>, Kedar I.<sup>3</sup>, Ozalvo R.<sup>1</sup>, Sela S.<sup>1</sup>, Ber Y.<sup>1</sup>, Baniel J.<sup>1</sup>  
**Institutes:**<sup>1</sup>Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel, <sup>2</sup>Rabin Medical Center, Dept. of Imaging, Petah Tikva, Israel, <sup>3</sup>Rabin Medical Center, The Raphael Recanati Genetics Institute, Petah Tikva, Israel
- 237 **Is further screening of Asian men with low baseline prostate-specific antigen levels ( $\leq$  1.0 ng/ml) worthwhile?**  
By: Urata S., Kitagawa Y., Mizokami A.  
**Institutes:**Kanazawa University, Dept. of Urology, Kanazawa, Japan
- 238 **The use of prostate-specific antigen screening in purchased versus direct care settings: Data from the TRICARE military database**  
By: Gild P.<sup>1</sup>, Von Landenberg N.<sup>1</sup>, Cole A.<sup>1</sup>, Jiang W.<sup>2</sup>, Lipsitz S.<sup>2</sup>, Learn P.<sup>3</sup>, Sun M.<sup>1</sup>, Choueiri T.<sup>4</sup>, Nguyen P.<sup>5</sup>, Chun F.<sup>6</sup>, Fisch M.<sup>6</sup>, Kibel A.<sup>1</sup>, Menon M.<sup>7</sup>, Sammon J.<sup>7</sup>, Koehlmoos T.<sup>8</sup>, Haider A.<sup>2</sup>, Trinh Q-D.<sup>1</sup>  
**Institutes:**<sup>1</sup>Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery

and Center For Surgery and Public Health, Boston, United States of America, <sup>2</sup>Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, United States of America, <sup>3</sup>Uniformed Services University of The Health Sciences, Dept. of Surgery, Bethesda, United States of America, <sup>4</sup>Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dept. of Medical Oncology, Boston, United States of America, <sup>5</sup>Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, <sup>6</sup>University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, <sup>7</sup>Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, <sup>8</sup>Uniformed Services University of The Health Sciences, Dept. of Preventive Medicine and Biostatistics, Bethesda, United States of America

- 239 **Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA  $\geq$  1ng/ml?**  
**By:** [Callerot P.](#)<sup>1</sup>, Moineau M-P.<sup>2</sup>, Cussenot I.<sup>3</sup>, Baschet F.<sup>3</sup>, L' Her J.<sup>1</sup>, Doucet L.<sup>1</sup>, Cancel-Tassin G.<sup>3</sup>, Cormier L.<sup>4</sup>, Mangin P.<sup>3</sup>, Cussenot O.<sup>5</sup>, Fournier G.<sup>1</sup>, Valeri A.<sup>1</sup>  
**Institutes:**<sup>1</sup>Brest University Hospital, Dept. of Urology, Brest, France, <sup>2</sup>Brest University Hospital, Nuclear Medecine Laboratory, Brest, France, <sup>3</sup>Tenon University Hospital, CeRePP (Centre De Recherche Sur Les Pathologies Prostatiques), Paris, France, <sup>4</sup>Dijon University Hospital, Dept. of Urology, Dijon, France, <sup>5</sup>Tenon University Hospital, Dept. of Urology, Paris, France
- 240 **Risk of prostate-cancer death at 20 years stratified by midlife PSA and a panel of four kallikrein markers from a representative cohort of 11,506 healthy unscreened men aged 45-74**  
**By:** Sjoberg D.D.<sup>2</sup>, Vickers A.J.<sup>2</sup>, Assel M.<sup>2</sup>, Dahlin A.<sup>3</sup>, Carlsson S.<sup>1</sup>, Poon B.Y.<sup>2</sup>, Ulmert D.<sup>1</sup>, [Lilja H.G.](#)<sup>1</sup>  
**Institutes:**<sup>1</sup>Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, <sup>2</sup>Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America, <sup>3</sup>Lund University, Clinical Microbiology, Malmo, Sweden
- 241 **Inclusion of mpMRI into the European Randomized study of Screening for Prostate Cancer (ERSPC) risk calculator: A new proposal to improve the accuracy of prostate cancer detection**  
**By:** [Dell'Oglio P.](#)<sup>1</sup>, Stabile A.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Brembilla G.<sup>2</sup>, Maga T.<sup>1</sup>, Cristel G.<sup>2</sup>, Kinzikееva E.<sup>1</sup>, Losa A.<sup>1</sup>, Esposito A.<sup>2</sup>, Cardone G.<sup>2</sup>, De Cobelli F.<sup>2</sup>, Del Maschio A.<sup>2</sup>, Gaboardi F.<sup>1</sup>, Montorsi F.<sup>1</sup>, Briganti A.<sup>1</sup>  
**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy
- 242 **Head-to-head comparison of commonly used international prostate cancer risk calculators for prostate biopsy**  
**By:** Pereira-Azevedo N.<sup>1</sup>, [Verbeek J.](#)<sup>1</sup>, Nieboer D.<sup>2</sup>, Steyerberg E.<sup>2</sup>, Roobol M.<sup>1</sup>  
**Institutes:**<sup>1</sup>Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, <sup>2</sup>Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands
- 243 **Outcomes of PSA-based prostate cancer screening among men using non-steroidal anti-inflammatory drugs**  
**By:** [Murtola T.](#)<sup>1</sup>, Vettenranta A.<sup>2</sup>, Talala K.<sup>3</sup>, Taari K.<sup>4</sup>, Stenman U.-H.<sup>5</sup>, Tammela T.<sup>1</sup>, Auvinen A.<sup>6</sup>  
**Institutes:**<sup>1</sup>Tampere University Hospital, Dept. of Urology, Tampere, Finland, <sup>2</sup>University of Tampere, School of Medicine, Tampere, Finland, <sup>3</sup>Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, <sup>4</sup>Helsinki University, School of Medicine, Helsinki, Finland, <sup>5</sup>Helsinki University Hospital, Dept. of Biochemistry, Helsinki, Finland, <sup>6</sup>University of Tampere, School of Health Sciences, Tampere, Finland
- 244 **Decreasing screening efficacy with increasing age: Results from a population-based screening trial - Swiss ERSPC (Aarau)**  
**By:** [Prause L.](#)<sup>1</sup>, Wyler S.<sup>1</sup>, Moltgen T.<sup>1</sup>, Huber A.<sup>2</sup>, Grobholz R.<sup>3</sup>, Manka L.<sup>4</sup>, Recker F.<sup>1</sup>, Kwiatkowski M.<sup>1</sup>  
**Institutes:**<sup>1</sup>Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, <sup>2</sup>Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, <sup>3</sup>Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, <sup>4</sup>Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany

- 245 **Stage distribution of prostate cancer at a tertiary care oncology centre in India - reflections of an unscreened population**  
**By:** [Prakash G.](#)<sup>1</sup>, Bakshi G.<sup>1</sup>, Shinde R.<sup>2</sup>, Bhamre R.<sup>2</sup>, Murthy V.<sup>3</sup>, Rent E.<sup>4</sup>, Pal M.<sup>1</sup>, Mahantshetty U.<sup>3</sup>, Menon S.<sup>5</sup>  
**Institutes:**<sup>1</sup>Tata Memorial Hospital, Dept. of Surgical Oncology(urooncology), Mumbai, India, <sup>2</sup>Tata Memorial Hospital, Dept. of Surgical Oncology, Mumbai, India, <sup>3</sup>Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, <sup>4</sup>AJ Shetty Hospital, Dept. of Surgical Oncology, Mangalore, India, <sup>5</sup>Tata Memorial Hospital, Dept. of Surgical Pathology, Mumbai, India
- \*246 **The diverse genomic landscape of low-risk prostate cancer**  
**By:** [Cooperberg M.](#)<sup>1</sup>, Erho N.<sup>2</sup>, Chan J.<sup>3</sup>, Feng F.<sup>3</sup>, Cowan J.<sup>3</sup>, Simko J.<sup>3</sup>, Ong K.<sup>2</sup>, Alshalalfa M.<sup>4</sup>, Kolisnik T.<sup>2</sup>, Margrave J.<sup>2</sup>, Aranes M.<sup>2</sup>, Du Plessis M.<sup>2</sup>, Buerki C.<sup>4</sup>, Zhao S.<sup>2</sup>, Tenggara I.<sup>3</sup>, Davicioni E.<sup>2</sup>, Carroll P.<sup>3</sup>  
**Institutes:**<sup>1</sup>University of California, Dept. of Urology, San Francisco, United States of America, <sup>2</sup>GenomeDx, San Diego, United States of America, <sup>3</sup>UCSF, Dept. of Urology, San Francisco, United States of America, <sup>4</sup>GenomeDx, , San Diego, United States of America
- \*247 **A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)**  
**By:** [Arsov C.](#)<sup>1</sup>, Becker N.<sup>2</sup>, Herkommer K.<sup>3</sup>, Gschwend J.<sup>3</sup>, Imkamp F.<sup>4</sup>, Kuczyk M.<sup>4</sup>, Hadaschik B.<sup>5</sup>, Hohenfellner M.<sup>5</sup>, Siener R.<sup>6</sup>, Kristiansen G.<sup>7</sup>, Antoch G.<sup>8</sup>, Albers P.<sup>1</sup>  
**Institutes:**<sup>1</sup>University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, <sup>2</sup>German Cancer Research Center Heidelberg, Division of Cancer Epidemiology (C020), Heidelberg, Germany, <sup>3</sup>Technische Universitaet Muenchen, Dept. of Urology, Munich, Germany, <sup>4</sup>Hanover Medical School, Dept. of Urology, Hanover, Germany, <sup>5</sup>University of Heidelberg, Dept. of Urology, Heidelberg, Germany, <sup>6</sup>University of Bonn, Dept. of Urology, Bonn, Germany, <sup>7</sup>University of Bonn, Dept. of Pathology, Bonn, Germany, <sup>8</sup>University of Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany